Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 84 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Uncontrolled Hypertension Clear all
Completed Phase 2 Interventional Results available

An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

NCT05562934
View directory record Official record
Conditions
Resistant Hypertension
Interventions
XXB750 drug, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Anniston, Alabama • Birmingham, Alabama • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 2 Interventional

A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

NCT05769608
View directory record Official record
Conditions
Hypertension
Interventions
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Drug
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
104
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 21, 2026, 5:31 PM EDT
Enrolling by invitation No phase listed Observational

Implementation of Effective Hypertension Management Approaches: OSF HealthCare

NCT07450222
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
Not listed
Lead sponsor
Colleen J Klein
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional

Renal Denervation in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4

NCT01972139
View directory record Official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions
Renal Denervation using the Symplicity Renal Denervation System, Sham Renal Denervation, Renal Angiography
Device · Other
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Atlanta, Georgia • Durham, North Carolina • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 21, 2026, 5:31 PM EDT
Recruiting Not applicable Interventional

Sequential Multiple Assignment Randomized Trial to Reduce Food Insecurity

NCT07031739
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
Resource information, Community Health Worker (CHW) assistance, Medically-tailored Meals (MTM)
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 21, 2026, 5:31 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients

NCT01602367
View directory record Official record
Conditions
Hypertension
Interventions
BMS-823778, Placebo matching with BMS-823778
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
22
States / cities
Jonesboro, Arkansas • Los Angeles, California • Palm Springs, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled Hypertension

NCT05314439
View directory record Official record
Conditions
Hypertension
Interventions
ION904, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Cypress, California • Los Angeles, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension

NCT05001945
View directory record Official record
Conditions
Hypertension, Renal
Interventions
MLS-101 (Part I), Placebo (Part I), Placebo (Part II), MLS-101 (Part II)
Drug · Other
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
44
States / cities
Lincoln, California • Torrance, California • Tustin, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional Results available

Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension

NCT01673373
View directory record Official record
Conditions
Renal Artery Stenosis, Hypertension, Renovascular
Interventions
iCAST™ Rx Stent System
Device
Lead sponsor
Atrium Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
12
States / cities
Fremont, California • Loveland, Colorado • Clearwater, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension

NCT00277472
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan/Hydrochlorothiazide, HCTZ
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Oct 21, 2026, 5:31 PM EDT
Not listed Not applicable Interventional

Internet-based Positive Psychological Intervention for Hispanic/Latino Adult With Hypertension in a Primary Care Setting

NCT03892057
View directory record Official record
Conditions
Uncontrolled Hypertension, Cardiovascular Risk Factor
Interventions
Internet-based Positive Psychological Intervention
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PTSC: Improving Hypertension Control Among Poor Midlife African American Women

NCT04371614
View directory record Official record
Conditions
Uncontrolled Hypertension, BMI, Stress, Medication Adherence
Interventions
Prime Time Sister Circle
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
40 Years to 75 Years · Female only
Enrollment
359 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 4 Interventional Results available

The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy

NCT00666536
View directory record Official record
Conditions
Hypertension
Interventions
valsartan and amlodipine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reducing Inequities in Care of Hypertension, Lifestyle Improvement for Everyone (RICH LIFE Project)

NCT02674464
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
Provider Audit-Feedback, Stratified by Race and Ethnicity, Blood Pressure Measurement Standardization, System Level Leadership Intervention, Collaborative Care Team Intervention, Community Health Worker Referral, Specialist Care Consultation
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 100 Years
Enrollment
1,820 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional

How Safe and Effective is Micropulse Transscleral Cyclophotocoagulation in Patients With Uncontrolled Glaucoma?

NCT02627352
View directory record Official record
Conditions
Glaucoma
Interventions
Micropulse Transscleral Cyclophotocoagulation
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
20 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

A Study of CIN-107 in Patients With Uncontrolled Hypertension

NCT05137002
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
CIN-107, Placebo
Drug
Lead sponsor
CinCor Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
63
States / cities
Saraland, Alabama • Tucson, Arizona • Encinitas, California + 55 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx

NCT04083222
View directory record Official record
Conditions
Hypertension
Interventions
Placebo, ISIS 757456
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Tustin, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 3 Interventional

Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor

NCT02007629
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Riociguat (Adempas, BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
La Jolla, California • Sacramento, California • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 21, 2026, 5:31 PM EDT
Recruiting Phase 2 Interventional

Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

NCT07090161
View directory record Official record
Conditions
Hypertension, Uncontrolled Hypertension
Interventions
iloperidone, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
28
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 4 Interventional Results available

An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)

NCT01338636
View directory record Official record
Conditions
Exercise-induced Pulmonary Arterial Hypertension
Interventions
Ambrisentan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional Results available

SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System

NCT02439775
View directory record Official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions
Symplicity Spyral™ multi-electrode renal denervation system, Sham Procedure
Device · Procedure
Lead sponsor
Medtronic Vascular
Industry
Eligibility
20 Years to 80 Years
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
32
States / cities
Huntsville, Alabama • Stanford, California • New Haven, Connecticut + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 4 Interventional

The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension

NCT00562809
View directory record Official record
Conditions
Hypertension
Interventions
IRBESARTAN
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 27, 2007 · Synced Oct 21, 2026, 5:31 PM EDT
Recruiting Phase 3 Interventional

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

NCT07181109
View directory record Official record
Conditions
High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
Interventions
Zilebesiran, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
11,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
272
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 216 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional

Integrated Population Program for Diabetic Kidney Disease

NCT02418091
View directory record Official record
Conditions
Diabetic Kidney Disease, Uncontrolled Hypertension
Interventions
Telehealth
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Oct 21, 2026, 5:31 PM EDT